tm logo
A2 BIO
Live/Pending
FIRST EXTENSION - GRANTED

granted

on 19 Aug 2024

Last Applicant/ Owned by

30301 Agoura Road, Suite 210

Agoura Hills

CA

91301

Serial Number

97796903 filed on 15th Feb 2023

Registration Number

N/A

Correspondent Address

Joi A. White

Joi A. White CARR & FERRELL LLP

SAN MATEO, CA 94402

United States

Filing Basis

1. intent to use

2. intent to use current

Disclaimer

NO DATA

A2 BIO

medical research services; pharmaceutical and biopharmaceutical research and development services; provision of medical and scientific research information in the fields of therapeutics, biotherapeutics, medicines, pharmaceuticals; identification and development of, therapeutic targets for others for the treatment and prevention of cancer, inflammation and inflammatory diseases; development of the Read More

Classification Information


Class [042]
Computer & Software Services & Scientific Services


medical research services; pharmaceutical and biopharmaceutical research and development services; provision of medical and scientific research information in the fields of therapeutics, biotherapeutics, medicines, pharmaceuticals; identification and development of, therapeutic targets for others for the treatment and prevention of cancer, inflammation and inflammatory diseases; development of therapeutics and cell therapies for treatment and prevention of cancer, inflammation, and inflammatory diseases; research and development of therapeutics and cell therapies targeting targets lost in tumors for the treatment and prevention of cancer, inflammation and inflammatory diseases; biotechnology research, development, testing and analysis for the treatment of cancer, inflammation, and inflammatory diseases; scientific research and development services; providing scientific information relating to treatment and prevention of cancer, inflammation and inflammatory diseases; research, development, engineering and testing services in the fields of therapeutics, cell therapies, biologics, medicine, and pharmaceuticals; medical laboratory services, namely, tissue material processing and analysis in the field of autologous and allogeneic biologic preparations for medical use; biotechnology laboratory services; scientific and medical laboratory services; genetic engineering services


First Use Date in General

N/A

First Use Date in Commerce

N/A

Class [040]
Treatment & Processing of Materials Services


Custom manufacturing of therapeutics, biotherapeutics, medicines, and pharmaceuticals; manufacturing of cells, therapeutics and cell therapies for the treatment and prevention of cancer, inflammation and inflammatory diseases; biomanufacturing for others, namely, manufacturing of cells, therapeutics and cell therapies for the treatment and prevention of cancer, inflammation and inflammatory diseases using biological cells, in the manufacturing process; cell therapy manufacturing for others; autologous and allogeneic cell manufacturing for others; manufacturing services for others in the fields of therapeutics, cell therapies, biologics, medicine, and pharmaceuticals; providing technical information in the field of pharmaceutical manufacturing; custom manufacturing and engineering of biological cells, cellular targets, proteins, and antibodies for others for treatment and prevention of cancer, inflammation and inflammatory disease


First Use Date in General

N/A

First Use Date in Commerce

N/A

Class [005]
Pharmaceutical Products


Therapeutics in the nature of cells, proteins and protein complexes for the treatment and prevention of cancer, inflammation, and inflammatory diseases; biotherapeutics for the treatment and prevention of cancer, inflammation, and inflammatory diseases; medicines for the treatment and prevention of cancer, inflammation, and inflammatory diseases; pharmaceutical products for the treatment and prevention of cancer, inflammation, and inflammatory diseases; therapeutic targets, namely, proteins or protein complexes, for the treatment and prevention of cancer, inflammation and inflammatory diseases; therapeutic cells, therapeutic proteins and therapeutic antibodies for human use for the treatment and prevention of cancer, inflammation and inflammatory diseases; therapeutics and cell therapies in the nature of cells, proteins and protein complexes for the treatment of cancer, inflammation, and inflammatory diseases; engineered cell therapies in the nature of cells, proteins and protein complexes for medical purposes, namely, the treatment and prevention of cancer, inflammation and inflammatory diseases; engineered cell therapy platforms consisting of modified cells, cell receptors, proteins and protein complexes; cell platforms consisting of modified cells, cell receptors, proteins and protein complexes for the treatment and prevention of cancer, inflammation and inflammatory diseases; technology platforms for developing and engineering therapeutic cells, therapeutic proteins, therapeutic antibodies, therapeutics and cellular therapies for the treatment and prevention of cancer, inflammation, and inflammatory diseases; platform for autologous and allogeneic cell manufacturing; therapeutics and cell therapies targeting targets lost in tumors for the treatment and prevention of cancer, inflammation and inflammatory diseases; gene therapy products, namely, genetically engineered tissues for transplant purposes


First Use Date in General

N/A

First Use Date in Commerce

N/A

Mark Details


Serial Number

No 97796903

Mark Type

No Service Mark

Attorney Docket Number

No T-4935 US

44D Filed

No

44D Current

No

44E filed

No

44E Current

No

66A Filed

No

66A Current

No

Current Basis

No

No Basis

No

Legal History


Show more

Status DateAction Taken
19th Aug 2024SOU EXTENSION 1 FILED
19th Aug 2024SOU EXTENSION 1 GRANTED
19th Aug 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
19th Aug 2024SOU TEAS EXTENSION RECEIVED
20th Feb 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
26th Dec 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
26th Dec 2023PUBLISHED FOR OPPOSITION
06th Dec 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
17th Nov 2023APPROVED FOR PUB - PRINCIPAL REGISTER
17th Nov 2023EXAMINER'S AMENDMENT ENTERED